1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Generalized Myasthenia Gravis (gMG)—Market Insights, Epidemiology, and Market Forecast—2028

Generalized Myasthenia Gravis (gMG)—Market Insights, Epidemiology, and Market Forecast—2028

  • August 2019
  • 215 pages
  • ID: 5805134
  • Format: PDF
  • By Delve Insight


Table of Contents

‘Generalized Myasthenia Gravis (gMG)—Market Insights, Epidemiology, and Market Forecast—2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of gMG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted market size of Generalized Myasthenia Gravis (gMG) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028
Generalized Myasthenia Gravis (gMG) – Disease Understanding and Treatment Algorithm
The Generalized Myasthenia Gravis (gMG) market report gives a thorough understanding of the Myasthenia Gravis by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myasthenia Gravis in the US, Europe, and Japan.
Generalized Myasthenia Gravis (gMG) Epidemiology
The Generalized Myasthenia Gravis (gMG) epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Generalized Myasthenia Gravis (gMG) in the 7MM. The epidemiology is segmented by total diagnosed prevalent cases, auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK) and Japan from 2017–2028.
According to the analyst, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017. The estimates suggest a higher diagnosed prevalence of gMG in the United States with 32,188 cases in 2017. Among EU5, Spain had the highest diagnosed prevalent population of Gmg, whereas France had the lowest cases.
Generalized Myasthenia Gravis (gMG) Drug Chapters
This segment of the Generalized Myasthenia Gravis (gMG) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of Generalized Myasthenia Gravis (gMG) is mainly accounted by symptomatic treatments comprising acetylcholinesterase Inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and procedures (thymectomy).
Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies, it has significantly impacted the market size of Myasthenia Gravis after its launch.
Generalized Myasthenia Gravis (gMG) Market Outlook
The Generalized Myasthenia Gravis (gMG) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the analyst, the market of Generalized Myasthenia Gravis in 7MM was found to be USD 2,602 million in 2017. The United States accounts for the largest market size of Generalized Myasthenia Gravis, in comparison to EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
This market is further expected to grow during the forecasted period of 2019–2028 owing to the launch of upcoming therapies. Detailed chapter for upcoming therapies, like Rozanolixizumab (UCB Pharma); CFZ533 (Novartis); Efgartigimod (Argenx); Zilucoplan (Ra Pharmaceuticals); Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); Ravulizumab (Alexion Pharmaceuticals); IMVT-1401 (Immunovant); M281 (Momenta Pharmaceuticals); CV-MGO1(CuraVac), and others have also been covered in the report, are expected to enter the MG market by 2028. The market is further divided based on the available and upcoming drugs in to first and second-line of therapies.
Generalized Myasthenia Gravis (gMG) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Generalized Myasthenia Gravis (gMG) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Generalized Myasthenia Gravis (gMG) Report
Key strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Generalized Myasthenia Gravis (gMG) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This report will help to develop Business Strategies by understanding the trends shaping and driving the Myasthenia Gravis market.
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Myasthenia Gravis (gMG) market.
• To understand the future market competition in the Generalized Myasthenia Gravis (gMG) market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) Global Clinical Trials Review, H1, 2019

Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) Global Clinical Trials Review, H1, 2019

  • $ 2500
  • May 2019

Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) ...

Tourette Syndrome - Pipeline Review, H2 2019

Tourette Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Tourette Syndrome - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H2 2019, provides an overview ...

Hepatic Encephalopathy - Pipeline Review, H2 2019

Hepatic Encephalopathy - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Hepatic Encephalopathy - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2019, provides ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on